EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY-NC 4.0

Efficacy and Safety of Fibroblast Growth Factor‐21 Analogs for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis: A Systematic Review and Meta‐Analysis

Changhyeon Jeong, Nayoung Han iD, Nakyung Jeon iD, Su-Jin Rhee iD, Christine E Staatz iD, Min-Soo Kim, In-Hwan Baek iD

Clinical Pharmacology & Therapeutics · 2024

DOI: 10.1002/cpt.3278 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Changhyeon Jeong und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Kyungsung University, Busan, Korea. Hauptthemen laut MEDLINE: Fibroblast Growth Factors, Metabolic Diseases, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea (NRF).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fibroblast growth factor (FGF)‐21 analogs are potential therapeutic candidates for metabolic dysfunction‐associated steatohepatitis (MASH). This systematic review and meta‐analysis aimed to assess the efficacy and safety of the FGF‐21 analogs, efruxifermin, pegbelfermin, and pegozafermin for MASH treatment. A comprehensive systematic review and meta‐analysis of randomized controlled trials from five major databases was conducted. Primary efficacy outcomes focused on liver histological improvement, while secondary efficacy outcomes encompassed reductions in liver fat content and improvements in biochemical parameters. Safety outcomes examined included treatment‐emergent adverse events (TEAEs), treatment‐related TEAEs, TEAEs leading to discontinuation, and serious TEAEs. Eight eligible studies involving 963 patients were included in this review. Compared with the placebo group, the FGF‐21 analog‐treated group exhibited significantly improved primary efficacy outcomes, specifically ≥1 stage improvement in fibrosis with no worsening of MASH (risk ratio [RR] = 1.83; 95% confidence interval [CI] = 1.27–2.62) and at least two‐point improvement in the non‐alcoholic fatty liver disease activity score with no worsening of fibrosis (RR = 2.85; 95% CI = 2.06–3.95). Despite an increased risk of TEAEs (RR = 1.17; 95% CI = 1.08–1.27) and treatment‐related adverse events (RR = 1.75; 95% CI = 1.40–2.19), FGF‐21 analogs exhibited an acceptable safety profile. FGF‐21 analogs were significantly better in achieving liver histological improvements and beneficial biochemical outcomes compared with placebo, with a tolerable safety pattern. These findings shed light on the efficacy and safety of FGF‐21 analogs and provide valuable evidence for their application as MASH therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fibroblast Growth FactorsMetabolic DiseasesNon-alcoholic Fatty Liver DiseaseHumansFatty LiverRandomized Controlled Trials as TopicTreatment Outcome

Substanzen

FGF21 protein, humanfibroblast growth factor 21Fibroblast Growth Factors

Autor:innen und Institutionen

  • College of Pharmacy, Kyungsung University, Busan, Korea.
  • College of Pharmacy, Jeju National University, Jeju, Korea.
  • College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan, Korea.
  • Department of Pharmacy, College of Pharmacy, Wonkwang University, Iksan, Korea.
  • School of Pharmacy, Pharmacy Australia Centre of Excellence, The University of Queensland, Brisbane, Queensland, Australia.
  • Functional Food & Drug Convergence Research Center, Industry-Academic Cooperation Foundation, Kyungsung University, Busan, Korea.

ORCID-Profile: Nayoung Han, Nakyung Jeon, Su-Jin Rhee, Christine E Staatz, In-Hwan Baek

Förderung

  • National Research Foundation of Korea (NRF)

Zitieren

APA

Jeong, C., Han, N., Jeon, N., Rhee, S. J., Staatz, C. E., Kim, M. S., & Baek, I. H. (2024). Efficacy and Safety of Fibroblast Growth Factor‐21 Analogs for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis: A Systematic Review and Meta‐Analysis. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3278

Vancouver

Jeong C, Han N, Jeon N, Rhee SJ, Staatz CE, Kim MS, et al. Efficacy and Safety of Fibroblast Growth Factor‐21 Analogs for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis: A Systematic Review and Meta‐Analysis. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3278

BibTeX
@article{Jeong2024,
  author = {Jeong, Changhyeon and Han, Nayoung and Jeon, Nakyung and Rhee, Su-Jin and Staatz, Christine E and Kim, Min-Soo and Baek, In-Hwan},
  title = {Efficacy and Safety of Fibroblast Growth Factor‐21 Analogs for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis: A Systematic Review and Meta‐Analysis},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1002/cpt.3278}
}
Kostenlos starten →